Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Preeclampsia
Interventions: Aspirin, Placebo Oral Tablet, Progesterone; Drug
Lead sponsor: John Uckele; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hypertension, Type2diabetes, Metabolic Syndrome, Obesity
Interventions: Medically Tailored Meals; Other
Lead sponsor: Amanda Shallcross; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congestive Heart Failure
Interventions: CoVa; Device
Lead sponsor: Aventyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions: Aspirin 81 mg, Aspirin 162 mg; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 10,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions: Valsartan and simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Artesia, California • Petaluma, California • Morrow, Georgia + 1 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: Diabetes, Hypertension
Interventions: Financial Incentive: Fixed Lottery; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside; Dietary Supplement · Drug
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Heart Failure, Hypertension
Interventions: Not listed
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Riverside, California

Conditions: Hypertension
Interventions: amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,422 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cardiovascular Disease, Hypertension, Diabetes
Interventions: m-health; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Uncontrolled Hypertension
Interventions: Clinical Decision Software - provider portal, Clinical Decision Software - patient portal; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Metformin, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: MI-BP; Other
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Diastolic Heart Failure, Hypertensive Heart Disease
Interventions: DASH/sodium-restricted diet (DASH/SRD), Control Diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension
Interventions: nebivolol; Drug
Lead sponsor: Jack Rubinstein; Other
Eligibility: 20 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: Omada Hypertension Program; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Nilotinib, Placebo to nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Interventions: Saliva sample, Health surveys; Genetic · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Hypertension, Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Search by objective public record fields.

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

Nutrition Outreach and Understanding: Research In Serving Hearts Through Healthy Eating And Tailored Support

Assess Measurements of Wireless Cardiac Output Device

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

SYL040012, Treatment for Open Angle Glaucoma

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

Take Charge of Your Diabetes

Effects of an Antioxidant Supplement on Blood Vessel Health

Monitoring Subjects With Fluid-Management Issues In the Home Environment

A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.

Evaluating CVD Medication Adherence Program in Low SES

Uncontrolled Hypertension Management (TEAM-HTN)

The Effects of Metformin on Blood Vessel Structure and Function

MI-BP: mHealth to Improve Blood Pressure Control

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

An Advanced Echocardiographic Evaluation of Nebivolol

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Rutgers University Study of the Genetics of Pulmonary Hypertension

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus